Aiosyn (AI) — Funding, Investors & Signals 2026

Aiosyn

Harnessing AI to Enhance Pathology Precision and Accelerate Biopharma Research

Founded 2021 11-50 employees Grant Total: $3.30M AI, Health Care +3

Aiosyn is a startup that is focused on utilizing artificial intelligence (AI) to enhance the precision of pathology diagnostics in cancer and chronic kidney diseases. The company's slogan, "Harnessing AI to Enhance Pathology Precision and Accelerate Biopharma Research," perfectly encapsulates its core mission. Founded in 2021, Aiosyn has developed pathology algorithms that aim to improve the accuracy of diagnostics in these critical areas of healthcare. One of the key aspects of Aiosyn's approach is its use of a modular Software as a Service (SaaS) model, allowing for seamless integration of its algorithms with existing pathology workflows. This not only streamlines the implementation process but also demonstrates the company's commitment to adaptability and scalability. Additionally, Aiosyn leverages its AI capabilities to enhance the efficiency of drug development studies for biopharmaceutical companies operating in the cancer and chronic kidney disease space. In terms of investment, Aiosyn recently secured a significant €1.30M grant investment on 09 May 2023. While the details of the investors involved in this round are undisclosed, this injection of funds is indicative of external confidence in the company's vision and potential for impact within the AI, health care, medical devices, pharmaceutical, and machine learning industries. Aiosyn's innovative approach and recent investment underscore its position as a promising player in the intersection of AI and healthcare.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	€1.30M	-		09 May 2023
Seed Round	€2.00M	3	Oost NL, Health Innovations +1	21 Dec 2022
Pre Seed Round	Undisclosed	2	Oost NL, LUMO labs	03 Feb 2022

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

€1.30M

09 May 2023

Seed Round

€2.00M

Oost NL, Health Innovations +1

21 Dec 2022

Pre Seed Round

Undisclosed

Oost NL, LUMO labs

03 Feb 2022

FAQ About Aiosyn

Harnessing AI to Enhance Pathology Precision and Accelerate Biopharma Research

Aiosyn was founded in 2021.

Aiosyn operates in AI, Health Care, Medical Devices, Pharmaceutical and Machine Learning. Its work centres on pathology algorithms, cancer diagnostics, chronic kidney disease diagnostics and biopharma research.

Aiosyn has approximately 11-50 employees.

Aiosyn has completed 3 funding rounds, raising a total of $3.30M. The latest funding stage is Grant.

Top alternatives and competitors to Aiosyn include Ibex Medical Analytics, Neurabot Lab, Maxwell Plus, contextflow, Deep Bio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Aiosyn and Ibex Medical Analytics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Aiosyn

General Information

Discover More

About Aiosyn

Funding Rounds & Investors (3)

Aiosyn Alternatives & Competitors

FAQ About Aiosyn